MedTrace Logo

Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil

NCT05630313 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-06-13

No results posted yet for this study

Summary

This protocol proposes to investigate genetic factors that may be involved in the pathogenesis of adverse events of interest with selected covid-19 vaccines: vaccine-induced immune thrombotic thrombocytopenia, and neurological adverse events, such as Guillain-Barré syndrome, acute disseminated encephalomyelitis and transverse myelitis, with the intention of identifying useful biomarkers in identifying people at higher risk, thus reducing the occurrence of these serious adverse events (SAE).

Conditions

  • Vaccine-induced Thrombotic Thrombocytopenia Syndrome
  • Guillain-Barre Syndrome
  • Acute Disseminated Encephalomyelitis
  • Transverse Myelitis

Sponsors & Collaborators

  • Oswaldo Cruz Foundation

    collaborator OTHER

  • The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)

    lead OTHER

Principal Investigators

  • Patrícia de Oliveira, MD · Instituto Fernandes Figueira

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-10-04
Primary Completion
2023-09-30
Completion
2023-09-30

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05630313 on ClinicalTrials.gov